Is Now the Critical Tipping Point for Progress with Immunotherapy in Resectable NSCLC? Where Are We Now and What’s to Come in 2021 and Beyond?

Time: 8:30 am
day: Day Two


  • Review historical data along with current approaches for potentially resectable NSCLC
  • Discuss drug development in NSCLC and why progress in resectable NSCLC has lagged behind advanced stages of disease
  • Describe emerging data, science, and future opportunities for immunotherapy to improve outcomes within resectable NSCLC, including the neoadjuvant, adjuvant and peri-adjuvant settings